期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 34, 期 6, 页码 635-645出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0000000000000787
关键词
Epstein-Barr virus; Epstein-Barr virus posttransplant lymphoproliferative disorder
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health [T32AI118690]
- Leukaemia Foundation
- Haematology Society of Australia and New Zealand (HSANZ) New Investigator PhD Scholarship
- NHMRC CRE [1116876, 1173791]
Management of EBV PTLD involves complex measures such as risk stratification, preemptive therapy, and balancing treatment options. Experimental therapies like donor-derived multipathogen and EBV specific CTLs show promise in prevention and treatment of EBV PTLD.
Purpose of review Management of Epstein-Barr virus posttransplant lymphoproliferative disorder (EBV PTLD) is complex, involving risk stratification, prevention and/or preemptive measures involving monitoring EBV DNAemia and balancing treatment options, using a combination of reduction of immune suppression, anti-B cell therapy, and cytotoxic T lymphocytes (CTLs). Recent findings The highest risk factor for the development of EBV PTLD in hematopoietic cell transplant (HCT) remains T cell depletion, with increasing use of antithymocyte globulin (ATG) or alemtuzumab in conditioning. In solid organ transplantation (SOT), the incidence of PTLD is highest among EBV seronegative recipients who are at risk for primary EBV infection following transplant in the first 12 months. Prevention is a critical component of the management of EBV PTLD. Although preemptive therapy remains standard of care, there continues to be heterogenicity and debate over the optimal choice of EBV DNA quantification and the threshold to use. Novel therapies such as donor-derived multipathogen and EBV specific CTLs for the prevention and third party CTLs for the treatment of EBV PTLD are promising, with rapidly expanding evidence, including large scale Phase III trials currently underway. Summary With an increasing number of risk groups for developing EBV PTLD in HCT and SOT, management strategies using prophylaxis or preemptive therapy remain standard of care, however the use of prophylactic or preemptive EBV specific or multipathogen CTLs show promising results and safety profiles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据